Filing summary
Registrant discrepancy: The supplied filing identifies the registrant as DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc. This is an unaudited Form 10-Q for the quarter ended March 31, 2014.
Business context and reporting period
DelMar is a development-stage cancer drug company with no product revenue. Its lead candidate, VAL-083, is being studied for refractory glioblastoma (GBM); the company also described development and partnership plans for lung cancer and other indications.
Key financial metrics
| Metric | Three months ended March 31, 2014 | Comparable period / prior balance |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $618,869 | $631,947 in Q1 2013 |
| General and administrative expense | $966,923 | $920,377 in Q1 2013 |
| Net loss | $3,198,607; $0.10 per share | $7,405,319; $0.30 per share in Q1 2013 |
| Operating cash used | $884,503 | $2,124,467 in Q1 2013 |
| Cash and cash equivalents | $3,474,150 | $4,136,803 at December 31, 2013 |
| Working capital | $3,313,942 | $4,069,261 at December 31, 2013 |
| Total assets | $3,754,153 | $4,318,748 at December 31, 2013 |
| Derivative liability | $5,857,991 | $4,402,306 at December 31, 2013 |
| Stockholders’ deficiency | $3,060,299 | $817,978 at December 31, 2013 |
Margins are not meaningful because the company reported no product revenue. The filing reports a $250,000 Valent loan, plus accrued interest, at 3% interest and payable on demand; management presented the balance as long-term based on expected repayment timing. The filing does not provide a separate clear total-debt figure beyond the loan and other reported liabilities.
Changes versus the prior comparable period
- Net loss narrowed by about $4.21 million. The comparison is substantially affected by Q1 2013 items: $2.71 million of derivative issue costs, a $598,000 share expense related to reducing future Valent royalties, and a larger derivative fair-value loss.
- Operating cash use fell by about $1.24 million. Cash declined by about $663,000 from year-end; Q1 financing proceeds were $221,850 from warrant exercises, versus substantial unit-offering proceeds in Q1 2013.
- R&D expense decreased about 2%; G&A expense increased about 5%. Excluding share-based compensation, management said both categories declined, citing lower clinical timing-related costs and lower one-time professional fees, respectively.
- The derivative liability rose about $1.46 million, including a $1.60 million quarterly fair-value loss. It is measured using a Level 3 valuation model and can cause significant reported earnings volatility.
Outlook, commentary, risks, and unusual items
- Management estimated existing cash would fund operations for approximately 9 to 12 months and planned to seek additional equity financing and/or strategic partnerships. The company warned that financing may not be available on acceptable terms and stated that substantial doubt exists about its ability to continue as a going concern.
- Management said the Phase I/II VAL-083 GBM trial had shown tolerability at tested doses, with no maximum tolerated dose yet reached; some patients had stable disease or tumor regression. These are interim findings, not proof of efficacy. The revised dose-escalation trial had reached 30 mg/m², with 40 mg/m² planned and reported as initiated in May 2014.
- The company planned to continue GBM development, advance preclinical work in non-small-cell lung cancer, and pursue commercial or development partners, including for China. VAL-083 was described as approved in China for certain uses, but not approved outside China.
- Funding needs depend on clinical progress, regulatory and manufacturing costs, intellectual-property expenses, and potential partnerships. If financing is insufficient, the company may delay, reduce, or discontinue programs. Management also cited comparatively weak intellectual-property protection in China.
- Derivative fair-value accounting, share-based compensation, and equity issued for services are notable noncash or valuation-sensitive items. The filing reports no legal proceedings and states that disclosure controls were effective, with no material internal-control changes during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for DelMar Pharmaceuticals, Inc., despite the request metadata naming Tuhura Biosciences, Inc.
- Assess the going-concern funding risk, management’s 9-to-12-month cash estimate, and the availability and terms of future financing.
- Review the trial’s full clinical evidence and subsequent progress; the filing’s efficacy statements are interim and uncontrolled.
- Examine the assumptions and potential volatility of the $5.86 million Level 3 derivative liability and its effect on reported losses.
- Reconcile the share-count disclosures: the filing reports 32,082,132 shares on an as-exchanged basis at March 31 and 25,295,549 shares outstanding as of May 14, 2014. Also consider 22,392,696 outstanding warrants and 3,240,000 options, which could create dilution.